Feed NVAX
NV

Novavax NVAX · NASDAQ

$11.26 -12.17% (-$1.56)

Market cap
$2.11B
Enterprise value
$2.22B
P/E
-
Forward P/E
-
PEG
-
P/S
5.1x
P/FCF
-
EV/EBITDA
-
ROIC
-36.5%
Bruto marža
77.9%
Neto marža
-59.9%
Dividend yield
-
Payout ratio
-
Neto dolg/EBITDA
-
Beta
2.44
Free float
87.6%

O podjetju

Novavax (NVAX) is a biotechnology company focused on developing innovative vaccine technologies. Their main goal is to provide effective and safe vaccinations against infectious diseases. Currently, Novavax is dedicated to the development of a vaccine for respiratory viruses, including COVID-19. Novavax stock is suitable for investors who closely follow the biotechnology industry and seek opportunities in the healthcare sector. Add Novavax stock to your watchlist on Bulios and stay informed about the latest developments and news regarding this innovative biotech company.

Sector

Healthcare

Industry

Biotechnology

CEO

John Charles Jacobs

Employees

749

Headquarters

Gaithersburg

Vrednotenje

Je današnja cena primerna?

Rast in ocene

Ali podjetje raste in kaj sledi?

Donosnost in kakovost

Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?

Finančno zdravje

Ali zmore svoj dolg?

Kapital in dividende

Kaj podjetje počne z zasluženim denarjem?

Analitiki

Kaj menijo strokovnjaki in ali se to spreminja?

Lastniki in insajderji

Kdo ima delnice in kaj počne vodstvo?

Segmenti

Kateri del podjetja raste?

Primerjava s konkurenco

Kako se primerja s podobnimi podjetji?

Cena in tveganje

Kako se delnica obnaša?

Izkazi

Vse številke

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.